GILD

Nasdaq

GILEAD SCIENCES, INC.

Health Care, Biotechnology

$133.21

close 7 Aug 2026

+10.58%

52-week change

$165.31B

market cap

$108.46

$157.29

52-week range

Valuation

Market cap$165.31B

P/E (TTM / 5y avg)-50.08x114.71x

Forward P/E (FY2026 / FY2027)—13.49x

PEG (TTM / fwd)——

P/S (TTM)5.43x

P/B13.98x

EV/EBITDA (TTM)-90.10x

FCF yield (TTM)7.83%

Cash flow & dividend

FCF (TTM)$12.94B

FCF per share (TTM)$10.43

FCF margin (TTM)42.50%

Dividend yield (indicated / 5y avg)2.46%3.62%

Annualized dividend$3.28

Payout ratio (EPS / FCF)-125.56%31.43%

Growth & quality

Revenue YoY, latest Q+10.18%

Diluted EPS YoY, latest Q-641.67%

Operating margin (TTM)-8.20%

Net margin (TTM)-10.64%

ROE (latest FY)37.48%

Net debt / EBITDA (TTM)—

Interest coverage (TTM)-2.50

Price

+87.20%+13.41%/yrover 5y

Weekly closes · split-adjusted

close 7 Aug 2026

Fundamentals

Fiscal years, last 10, CAGR chips on growth series, plus a dimmed trailing-twelve-month bar

Revenue

5Y CAGR +3.58%10Y CAGR -1.03%

Diluted EPS

5Y CAGR +132.41%10Y CAGR -5.48%

FCF per share

5Y CAGR +4.27%10Y CAGR -5.66%

Operating cash flow

5Y CAGR +4.17%10Y CAGR -7.24%

Free cash flow

5Y CAGR +4.69%10Y CAGR -7.45%

Dividends per share

5Y CAGR +2.61%10Y CAGR +9.97%

Payout ratio

FCF payout ratio

Operating margin

FCF margin

Return on equity

Return on capital employed

Shares outstanding

5Y CAGR -0.21%10Y CAGR -1.35%

Net debt / EBITDA

Interest coverage

Earnings

Street estimates, not SEC filings

Next / Q3 FY26

Date28 Oct 2026

EPS estimate$2.27

Revenue estimate$7.93B

Last reported

Date—

EPS——

Revenue——